oraCMU® · oraCMS1®
oraCMU® and oraCMS1® are OraPharm’s patented probiotics.
Both probiotic strains that promote oral health were isolated from
the saliva of
460 South Korean kids, who had healthy mouth.
Strain Names: Weissella cibaria CMU, CMS1
Special Probiotic Strains
Patented by OraPharm
-
Probiotics found
in the healthy mouths
of 460 South Korean kids
between 4 and 7 -
Probiotics
approved
by MFDS
for use as food
ingredients -
A combination of
6 mechanisms of action
which maximizes
synergistic
effects in oral cavity -
2 ROK patents
& 1 U.S. patent
OraPharm
has never stopped studying
in order to improve oral health.
Learn More About Us
Beneficial Roles of oraCMU®·oraCMS1®
Reducing Halitosis and Inhibiting Bacteria That Cause Bad Breath
- 01. 8Breath improved after 8-week administration
(findings of the clinical trial) - 02. A decrease in VSC production(findings of the clinical trial)
- 03.Inhibition of smelly substances in bad breath caused by oral bacteria(a research paper)
Prevention of
Dental Caries
- 01. The decrease in dental plaque index(findings of the clinical trial)
- 02. Inhibition of plaque formation
(a research paper)
Periodontitis
- 01. Inhibition of factors causing inflammation of the gums
- 02. Reduction of periodontal tissue destruction
- 03. Reduction in gingival bleeding index
The Competitiveness of
OraPharm
Probiotics for oral health & Technology
-
Adhesive Properties
According to the results of the clinical trial, which compared probiotics’ adhesive properties, active oraCMU® was still observed on the surface of oral cavity of 84% of participants, who stopped taking oraCMU® 4 weeks ago.
-
Suppression of
Bad-Smelling CompoundsOraCMU® was proved to be the most effective in suppressing VSC and bad breath compared With 4 other probiotic strains.
-
Coaggregation with Bacteria
Which Cause Oral DiseasesA comparative study of coaggregation of probiotics with bacteria, which cause oral diseases, found that oraCMU® more effectively disrupts bacterial activities leading to halitosis and periodontitis and prevents oral diseases than all other probiotic strains concerned.
-
Antibacterial Activities against Bacteria
That Cause Halitosis or PeriodontitisA comparative study of antibacterial activities of probiotics found that oraCMU® is more effective to inhibit growth in bacteria which cause halitosis and periodontitis than all other probiotic strains concerned.
-
Low Caries Risk
A comparative study of PAV of probiotic strains in carbohydrates found that oraCMU® is the least likely to influence the development of dental caries.
-
Significant Reduction
in PlaqueThe clinical trial to investigate the efficacy of probiotic strains in preventing dental caries discovered that OraCMU® has greater inhibitory effects on plaque formation than probiotic strains provided by other companies.
-
Inhibition of Plaque Formation by
S. MutansA comparative study of probiotic strains’ inhibitory effects on plaque formation by bacteria(S. mutans) that cause dental caries discovered that oraCMU® inhibits plaque formation most efficiently.
A Combination of
Mechanisms of Action
-
1. Coaggregation
The Probiotics, which promote oral health and were patented by OraPharm, detect certain parts of pathogenic bacteria. The probiotics and pathogenic bacteria, therefore, can be easily combined. Coaggregation of the probiotics with pathogenic bacteria enables the probiotics to block the adherence of pathogenic bacteria to epithelial cells and teeth and contribute to the elimination of pathogenic bacteria.
-
2. The inhibition of the production of substances that contribute to dental plaque
Bacteria that cause dental caries metabolize sugars to produce sticky substances, which contribute to plaque formation. OraPharm’s patented probiotics inhibit such bacterial activities in the oral cavity, thereby blocking biofilm(tartar or dental plaque) formation.
-
3. Secretion of 4 antimicrobial substances
OraPharm’s patented probiotics secrete antimicrobial substances such as organic acids, hydronic peroxide, fatty acids, and bacteriocin outside of cells, thereby inhibiting the growth of bacteria which cause halitosis and periodontitis.
-
4. Competition with pathogens for binding sites on epithelial cells
OraPharm’s patented probiotics block the adherence of pathogens, which cause halitosis or periodontitis, to epithelial cells, thereby preventing various oral diseases.
-
5. Inhibition of enzymatic activities and expression of genes related to VSC production
OraPharm’s patented probiotics inhibit mgl gene expression in P. gingivalis, the bacteria which produce VSC, the main cause of bad breath. The probiotics also inhibit and block METase activities.
-
6. The inhibition of formation of substances that promote cellular inflammation
oraCMU® inhibits the production of substances(NO, IL1β, and IL6, all of which promote inflammation) induced by general probiotics for oral health.
Patents & Certificates
-
ROK Patent(Patent No. 10-0609992) Lactic Acid Bacteria Inhibiting Halitosis -
ROK Patent(Patent No. 10-1921309) Composition for Preventing or Improving
Dental Caries Comprising Weissella Cibaria Strain -
U.S. patent(US 7,250,162 B2) Lactic acid bacteria
inhibiting halitosis -
NeT Certificate An Application Technology for
Prevention of Bad Breath -
Authorization of Food Ingredients Given by MFDS Authorization to Use Weissella Cibaria
as a Food Ingredient
Oral probiotics?
Shop Now
TOP